Orthotopic and metastatic tumor model

With rich experience in surgical and imaging technologies, the R&D team of CIR Biopharma has built a mature in situ and metastatic tumor models platform for evaluating the effects of drugs on the tumor itself and the tumor microenvironment of the primary lesion in which it is located. This platform provides a more valuable preclinical evaluation tool for drugs targeting tumor stromal cells, tumor angiogenesis, tumor endocrinology, tumor metabolic pathways, and tumor-regulating cytokines, especially for tumor immunotherapy, gene therapy, and cell therapy. CIR Biopharma team can perform parallel multiple imaging markers and real-time assays, capable of simultaneously evaluating tumor growth, invasion, distal metastasis and survival in model animals.

Characteristics and advantages of orthotopic tumor model

PerkinElmer IVIS Spectrum Visible light 3D imaging system for small animals

Orthotopic, systemic & metastatic tumor models